Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood test flag hidden heart risks after stenting?

NCT ID NCT05131750

Knowledge-focused Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This study follows about 1,400 people with coronary heart disease who undergo a stent procedure, called PCI, to open blocked arteries. Even with standard treatment, these patients still face a risk of major heart events. Researchers will measure levels of a protein called hsCRP, a marker of inflammation, at multiple times over 5 years. The goal is to see whether persistent inflammation, known as residual inflammatory risk, predicts future heart attacks, strokes, or death.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If it works, this could help doctors identify heart patients who face higher risks after stenting, guiding more personalized follow-up care.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The results may not apply to all heart patients, and the 5-year follow-up may be too short to capture all events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,408 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2021

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with coronary heart disease completed all planned PCI during hospitalization

Ages

18 to 80 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants who understand and sign the informed consent form voluntarily; 2. Age ≥ 18 years old and ≤ 80 years old, regardless of sex; 3. The hospitalized patients with coronary heart disease undergoing PCI; 4. Complete all planned PCI during hospitalization Exclusion Criteria: 1. Patients do not receive standardized treatment according to guidelines after being diagnosed with coronary heart disease; 2. Uncontrolled infectious diseases during the screening period; 3. In the screening stage, patients with immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumor and so on; 4. Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapeutic drugs during the study period; 5. Surgical or interventional treatment was performed within 3 months before the screening period; 6. Pregnant women, lactating women or women of childbearing age who do not use effective contraceptives; 7. Participated in other clinical trials within 3 months before the screening period; 8. The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary heart disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Hirschsprung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HSCRP

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.